Some of my friends often ask me how long the survival period of glioma patients is. In fact, this question is very difficult to answer, especially for a specific patient. This is because there are many factors, including the tumor itself, the individual patient’s condition, and the treatment, that can directly affect the patient’s prognosis. For example, is the patient suitable for surgical treatment? What type of surgery is appropriate? How effective is the surgical resection? What type and grade of pathology is the tumor? Does radiation therapy need to be given? What is the timing and protocol of radiotherapy? Is chemotherapy needed? What kind of chemotherapy regimen is more appropriate? And so on. Deviations in any of these aspects may directly affect the patient’s prognosis. This means that a complete treatment plan should be tailored to the patient’s specific medical condition, and that the best prognosis, including the highest quality of life and the longest survival, is possible with the right treatment. This is the concept that glioma must be treated individually, as proposed at the First World Congress on Glioma. Glioma is the most prevalent of all neurological tumors. In recent years, there are more and more international research reports on the treatment of this tumor, and many doctors in China have started to pay attention to the research and treatment in this area. However, due to the lack of experience and understanding of international research developments, sometimes treatment methods that are not in line with modern treatment concepts are inevitably adopted. For example, since 2005, I have been doing my best to promote the idea that some low-grade gliomas do not require treatment and that the correct course of action is dynamic observation, or Wait and see in English, but this view was not accepted by patients and families, nor by my colleagues, and was even criticized. It was not until 2008, when the U.S. incorporated this view into the national glioma treatment guidelines, that this view was gradually understood by Chinese physicians who could see the guidelines. However, we should be aware that this view is only appropriate for the modern level of medical care, and if and when glioma is completely conquered, then this view should be eliminated as well. The emphasis of modern medicine is on evidence-based medicine, and individual experience has become insignificant, while what can really guide the clinical practice of medicine must be the common findings of the world’s multicenter research. It is becoming more and more difficult to become a good doctor, and it is necessary to update the concept and knowledge in time. In clinical practice, there are indeed individual doctors who lack the spirit of seeking truth from facts, over-exaggerate their own experience and so-called research results, and make treatment plans for patients at will. Therefore, as patients and their families should also learn to screen the truth, despite the lack of sufficient medical knowledge, but some medical common sense should be understood. Medical science is not mysterious, and doctors are also mortal, so they should carefully identify who has more evidence and reasoning. At present, the treatment of glioma is still difficult to achieve the expected results in many cases. However, with the clinical trials of immunotherapy and gene targeted therapy conducted in Europe and the United States in recent years, there has been a new improvement in the treatment of glioma. We have also been working on clinical trials in these areas. We believe that clinical trials for glioma treatment will be started in the near future, and we hope you can support our work. Finally, I would like to introduce you the average survival of some adult patients with glioma published in the United States in 2006, because it is an average is not equal to an individual, so I hope you will not take the right number, but just as a relevant medical knowledge to understand, in fact, medical miracles are happening every day. Tumor tissue type Average survival (months) Low-grade oligodendroglioma ~120 Low-grade astrocytoma ~60 Mesenchymal oligodendroglioma ~60 Mesenchymal astrocytoma ~36